Clinical Trial Update: A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating rebamipide as an adjuvant regimen to heal erosive esophagitis in gastroesophageal reflux disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erosive Esophagitis
• Gastroesophageal Reflux Disease

Drugs mentioned

• Mucosta (rebamipide)
• Rebamipide (rebamipide)

Snippet

Sponsor: YongChan Lee | Conditions: Gastroesophageal Reflux | Phase 4 | Status: COMPLETED